Detection of minimal residual disease in multiple myeloma using
cell-free DNA

a 2015

Detection of minimal residual disease in multiple myeloma using cell-free DNA

KUBACZKOVÁ, Veronika; Lenka SEDLAŘÍKOVÁ; Lenka BEŠŠE; Roman HÁJEK; Sabina ŠEVČÍKOVÁ et al.

Základní údaje

Originální název

Detection of minimal residual disease in multiple myeloma using cell-free DNA

Autoři

KUBACZKOVÁ, Veronika; Lenka SEDLAŘÍKOVÁ; Lenka BEŠŠE; Roman HÁJEK a Sabina ŠEVČÍKOVÁ

Vydání

The Biomania Student Scientific Meeting 2015, 2015

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00091269

Organizační jednotka

Lékařská fakulta

ISBN

978-80-210-7933-5

Klíčová slova anglicky

cell-free DNA; multiple myeloma; minimal residual disease

Štítky

EL OK

Změněno: 19. 10. 2016 13:04, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Cell-free DNA (cf-DNA) detected in serum of peripheral blood has recently become a suitable minimally invasive diagnostic tool for diagnosis and monitoring of a variety of malignant diseases including multiple myeloma (MM). MM is a malignant disease of plasma cells (PB). Despite significant advances in treatment, majority of patients relapse. Monitoring of minimal residual disease (MRD) allows identification of patients who are at risk of relapse. The golden standard for detection of MRD in MM is flow cytometric analysis of bone marrow cells (BM) and PCR-based methodology of a tumor marker - specific rearrangement of the immunoglobulin heavy chain (IGH). The aim of our study was to assess MRD in MM patients by detecting serum cf-DNA carrying a tumor-specific marker that was analyzed at the time of diagnosis of PB in BM. Using real-time PCR and droplet-digital PCR, we analyzed 61 serum samples obtained at the time of diagnosis and at various time point of treatment. Our results indicate the potential use of detection of cf-DNA in MM patients for disease monitoring. However, potential benefits and predictive value of cf-DNA need to be verified on a larger cohort of patients.

Citovat

KUBACZKOVÁ, Veronika; Lenka SEDLAŘÍKOVÁ; Lenka BEŠŠE; Roman HÁJEK a Sabina ŠEVČÍKOVÁ. Detection of minimal residual disease in multiple myeloma using cell-free DNA. In The Biomania Student Scientific Meeting 2015. 2015. ISBN 978-80-210-7933-5.

@proceedings{1357322,
   author = {Kubaczková, Veronika and Sedlaříková, Lenka and Bešše, Lenka and Hájek, Roman and Ševčíková, Sabina},
   booktitle = {The Biomania Student Scientific Meeting 2015},
   keywords = {cell-free DNA; multiple myeloma; minimal residual disease},
   language = {eng},
   isbn = {978-80-210-7933-5},
   title = {Detection of minimal residual disease in multiple myeloma using cell-free DNA},
   year = {2015}
}

TY  - CONF
ID  - 1357322
AU  - Kubaczková, Veronika - Sedlaříková, Lenka - Bešše, Lenka - Hájek, Roman - Ševčíková, Sabina
PY  - 2015
TI  - Detection of minimal residual disease in multiple myeloma using cell-free DNA
SN  - 9788021079335
KW  - cell-free DNA
KW  - multiple myeloma
KW  - minimal residual disease
N2  - Cell-free DNA (cf-DNA) detected in serum of peripheral blood has recently become a suitable minimally invasive diagnostic tool for diagnosis and monitoring of a variety of malignant diseases including multiple myeloma (MM). MM is a malignant disease of plasma cells (PB). Despite significant advances in treatment, majority of patients relapse. Monitoring of minimal residual disease (MRD) allows identification of patients who are at risk of relapse. The golden standard for detection of MRD in MM is flow cytometric analysis of bone marrow cells (BM) and PCR-based methodology of a tumor marker - specific rearrangement of the immunoglobulin heavy chain (IGH). The aim of our study was to assess MRD in MM patients by detecting serum cf-DNA carrying a tumor-specific marker that was analyzed at the time of diagnosis of PB in BM. Using real-time PCR and droplet-digital PCR, we analyzed 61 serum samples obtained at the time of diagnosis and at various time point of treatment. Our results indicate the potential use of detection of cf-DNA in MM patients for disease monitoring. However, potential benefits and predictive value of cf-DNA need to be verified on a larger cohort of patients.
ER  -

KUBACZKOVÁ, Veronika; Lenka SEDLAŘÍKOVÁ; Lenka BEŠŠE; Roman HÁJEK a Sabina ŠEVČÍKOVÁ. Detection of minimal residual disease in multiple myeloma using cell-free DNA. In \textit{The Biomania Student Scientific Meeting 2015}. 2015. ISBN~978-80-210-7933-5.

Přehled o publikaci